ArticleThe East African health research journal2025
Seroprevalence of Mumps among Patients Attending Selected Hospitals in Kenya.
Article in The East African health research journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mumps is a highly infectious viral disease that poses a significant public health concern despite presence of safe and effective vaccine. This study aimed to determine seroprevalence of mumps among patients attending selected hospitals in Coast and Central regions of Kenya, and to evaluate the demographic factors associated with mumps seropositivity. Methodology: This was a cross-sectional study where serum samples collected from patients attending Kiambu, Murang'a and Kilifi County hospitals were quantitatively tested for anti-mumps IgG antibodies using commercial enzyme linked immunosorbent assay (ELISA) kits. Sample size estimation was calculated using Cochran formula. A total of 451 volunteers were enrolled between October 2020 and November 2021. Ethical approval was obtained from Institutional Review Board of Kenya Medical Research Institute Scientific and Ethics Review Unit. Statistical analyses were conducted using Statistical Package for the Social Sciences (SPSS) version 23.0 software. Results: The overall mumps seropositivity rate was 90.5% and geometric mean of mumps IgG titers (GMT) was 401.3 U/ml. Both seroprevalence and GMT were not significantly influenced by the demographic factors of the population under study. Nonetheless, there were trends of higher prevalence related to certain demographic groups. Seroprevalence increased with increasing age from 85% for less than 10-year-olds to 100% among those aged between 60 and 69 years ( Conclusions: The high mumps seroprevalence in this Kenyan population reflects widespread natural infection in the absence of vaccination. Age-related increases in antibody prevalence and geometric mean titres indicate cumulative exposure over time. These findings provide essential pre-vaccine baseline data and support the need for strengthened mumps surveillance and consideration of mumps vaccine inclusion in Kenya's national immunization program.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.